`
`Eliquis - FiercePharmaMarketing
`
`FiercePharmaMarketing
`
`Select another site Advertise Contact
`
`SEARCH
`
`Free Pharma Marketing News Brief
`
`Want to get the latest stories on business strategy, consumer advertising, new drug launches and more sent straight to your inbox? Join your fellow
`pharma marketing executives who subscribe to FiercePharmaMarketing for FREE!
`
`Click here for a sample.
`
`We never sell or give away your contact information. Our readers' trust comes first.
`
`EMAIL ADDRESS
`
`Eliquis
`
`The top 10 most-advertised prescription drug brands
`
`SH A R E
`
`Total: $219 million
`
`TOOLS
`
`Comment
`
`
`As the last to the market in the new generation of blood thinners,
`Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) overcompensated
`with ad spending on their joint-venture drug in 2014. Eliquis' paid
`media spending topped $219 million, an increase of 89% year over
`year.
`
`Last year, Eliquis was also approved as a treatment for deep vein
`thrombosis and pulmonary embolism, a smaller but important
`market sector, which may have spurred ad spending at the end of the year. The
`tight three-way competition likely was another factor in increased spending, as all
`three sought to stand out from the me-too crowd. Some speculated that Eliquis
`increased spending to take advantage of litigation woes for Bayer and Johnson &
`Johnson's ($JNJ) Xarelto and Boehringer Ingelheim's Pradaxa, with lawsuits
`involving bleeding complications mounting against the two. The increase in paid
`media comes on top of BMS and Pfizer's doling out of $8 million in doctor fees last
`year for Eliquis, the second-highest for any single drug, while the joint venture also
`expanded its sales force for the drug.
`
`Like most of the top-spending prescription drugs, the bulk of Eliquis advertising
`was spent on TV. Eliquis TV commercials bashed on previous generation drug
`warfarin, instead of taking on the current competition--market leader Xarelto and
`Pradaxa. Actors in the Eliquis TV ads outline direct comparisons to warfarin,
`explaining point by point how Eliquis is better.
`
`Still, results have been disappointing for BMS and Pfizer, which expected a
`blockbuster in Eliquis, but have yet to break the $1 billion barrier. Sales for 2014
`were $774 million.
`
`For more:
`BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt
`BMS, Pfizer's Eliquis gets a NICE boost in rivalry with Pradaxa, Xarelto
`Should Eliquis' surge make Xarelto fans very, very afraid? Not really, analyst says
`
`Special Report: The top 10 most-advertised prescription drug brands
`
`1
`
`2
`
`Cialis
`
`Lyrica
`
`6
`
`7
`
`Latuda
`
`Xeljanz
`
`FOLLOW US
`
`J O I N 2 4 , 0 0 0 + I N S I D E R S
`SIGN UP FOR OUR
`NEWSLETTER
`
`FiercePharmaMarketing is the leading source of
`pharma marketing news with a special focus on
`consumer advertising, DTC trends, new drug
`launches, and more. Join your fellow pharma
`marketing executives who get
`FiercePharmaMarketing via email. Sign up today!
`
`EMAIL ADDRESS
`
`POPULAR STORIES
`
`MOST SHARED
`
`THE LIBRARY: WEBINAR
`
`Rare Disease 20/20: A Look at the Challenges
`and Opportunities in Rare Disease Clinical
`R&D
`
`| TUESDAY, FEBRUARY 23 | 2PM ET /
`11AM PT | PRESENTED BY: BBK
`WORLDWIDE
`
`Join the National Organization for Rare
`Disorders (NORD), Xenon Pharmaceuticals
`and BBK Worldwide as they take a closer
`look at the challenges and opportunities in rare
`disease clinical R&D. Registration is free –
`click here.
`
`MORE ITEMS
`
`http://www.fiercepharmamarketing.com/special-reports/top-10-most-advertised-prescription-drug-brands-eliquis
`
`1/2
`
`Page 1 of 1
`
`SENJU EXHIBIT 2302
`LUPIN v. SENJU
`IPR2015-01097